Investor Relations

Investors

Biovalley turns scientific innovation into concrete business opportunities in Europe's largest economic sector.

Target

IPO 2026 — Euronext Growth Paris

Listing on Euronext Growth Paris planned for 2026, with an international expansion plan in European healthcare.

€1.650T

European Healthcare Market

Europe's largest economic sector, with structural growth supported by demographic trends

18–23%

Digital Health EU CAGR

Segment worth €70–100 billion growing at 18–23% per year

€100M

Founder's Previous Exit

Diego Bravar already delivered a €100M exit (TBS Group, 2017), later revalued at €1B in 2022

Proven Track Record

The Founder has already demonstrated the ability to create and successfully exit a healthcare company at €100M (later €1B).
Dual Growth Model

Combination of stable cash flows from operational SMEs and exponential growth potential from deep tech companies.
Defensible position

Patents (ChemoMaker®, Serichim), multi-year contracts (CB Sistemi) and regulatory barriers protect the competitive position.
Trieste Ecosystem

Trieste's researcher density (37.1 per 1,000 inhabitants, 4x the EU average) is a unique and non-replicable strategic asset.
Imminent listing

The path towards Euronext Growth Paris in 2026 offers a clear exit strategy for current investors.

Available documents:

Write to us to request information, documentation or to schedule a meeting with management.